





# Bioanalytical Technique: A quality check for pharmaceutical dosage forms


Keynote Speaker presentation 3<sup>rd</sup> International Conference on New Horizon in Drug Discovery and Development Process, 23<sup>rd</sup> February 2023

#### A. B. M. Helal Uddin

Department of Pharmaceutical Chemistry
Faculty of Pharmacy
International Islamic University Malaysia (IIUM)
Malaysia

#### Bioavailability?

Bioavailability refers to rate (how fast) and extent (the amount) to which the active substance is absorbed from a pharmaceutical dosage form and becomes available at the site of action (inside the body)



#### Bioequivalence

If two pharmaceutically identical medicines are also bioequivalent,



When administered in the same molar dose

- their bioavailability (rate and extent of absorption) are sufficiently similar.
- their effects should be basically the same.

It compare the rate & extent of absorption between test & reference product (to show that 2 drugs are bioequivalent to one another)

### BE REQUIREMENTS

BE is a requirement enforced by the NPRA, MOH(Ministry of health, Malaysia) for generics, to ensure quality, safety and efficacy of generics.

#### NPRA, Malaysia

#### After review the registration of generic products

- Received complaints on efficacy of the generic products.
- Decided to include BE studies as a requirement for generics (oral Immediate Release solid dosage form)
- To ensure that generics are therapeutically equivalent to the innovators → <u>clinically</u> <u>interchangeable</u>.



nternational Islamic University Malaysia

#### **Generic Medicines**



Reference	Definitions
DRGD (Malaysia)	A product that is essentially similar to a currently registered product in Malaysia
<b>WHO</b> * Multisource product	a pharmaceutical product, usually intended to be interchangeable with the innovator product, marketed after the expiry of patent or other exclusivity rights
USFDA	a medicine that is identical or bioequivalent to a brand name medicine in dosage form, safety, strength, route of adiministration, quality, performance, characteristic and intended use
EMA	a medicinal product which has the same qualitative and quantitative composition in active substances and the same pharmaceutical form as the reference medicinal product and whose bioequivalence with the reference medicinal product has been demonstrated by appropriate bioavailability studies

### **Comparator Drug**

# Innovator/comparator/reference products

A pharmaceutical product with which the multi-source product is intended to be interchangeable in clinical practice - WHO






#### BE requirements (Malaysia)

- Since Sept 2008
- > 229 products cancelled/suspended due to failure to fulfill BE requirements
- > 150 new applications rejected due to failure to submit adequate and satisfactory BE studies





#### Patented vs Generic



FFEED 011001100



### Bioanalysis

- Bioanalysis is defined as quantitative measurement of drugs in biological system (plasma, urine, and tissues).
- Bio analysis is very important in the field of drug development and generic formulation such as:
  - preclinical studies for new drugs
  - clinical studies in human plasma
  - therapeutic and toxicological concentrations.
  - pharmacokinetic studies for drugs
  - Bio equivalence of generic formulation

# Choice of Drugs

RANK	ATC	THERAPEUTIC GROUP	PUBLIC	PRIVATE	TOTAL
1	A10	Drugs used in diabetes	42.0556	6.9074	48.9630
2	C08	Calcium channel blockers	20.4728	10.6096	31.0823
3	C09	Agents acting on the renin-angiotensin system	19.7722	4.4640	24.2362
4	C07	Beta blocking agents	17.6028	2.5778	20.1806
5	C03	Diuretics	14.6048	4.3189	18.9237
6	M01	Antiinflammatory and antirheumatic products	3.0869	11.9973	15.0843
7	C10	Lipid modifying agents	8.6305	4.6590	13.2895
8	J01	Antibacterials for systemic use	4.7513	7.9885	12.7398
9	R06	Antihistamines for systemic use	4.3263	7.9234	12.2497
10	H02	Corticosteroids for systemic use	3.6126	8.1238	11.7364



#### Contd..

RANK	ATC	THERAPEUTIC GROUP	PUBLIC	PRIVATE	TOTAL
1	C08C A01	Amlodipine	26.7411	2.9817	29.7228
2	A10B B09	Gliclazide	23.7710	1.9930	25.7640
3	C09A A04	Perindopril	13.7130	0.6026	14.3156
4	A10B A02	Metformin	13.1892	1.1200	14.3092
5	C08C A05	Nifedipine	10.0114	1.5413	11.5527
6	C03A A03	Hydrochlorothiazide	10.6896	0.2586	10.9482
7	G03C A57	Conjugated estrogens	3.6887	6.9684	10.6570
8	C07A B02	Metoprolol	9.8532	0.1297	9.9829
9	C07A B03	Atenolol	7.9423	1.2049	9.1472
10	A10B B01	Glibenclamide	7.6174	0.8190	8.4364

### **Generic Products: Dry Dosage Forms**

Pharmacological Groups	Dosage Forms	
Antihypertensive (Amlodipine)	Tablets 5 mg Tablets 10 mg	
Antidiabetic (Gliclazide)	Tablet 80 mg	
Antihistamine (Cetirizine)	Tablet 10 mg	
Analgesic (Mefenamic Acid)	Capsule 250 mg Tablet 500 mg	




## **Amlodipine**

### Gliclazide

# Perindopril

# Specificity-Amlo



### **GLZ-Selectivity**





Fig. 10011001100


## Linearity-Amlo





nternational Islamic University Malaysia

#### **Linearity PER**





# Aims of setting up the Pharmaceutical Manufacturing Plant


Niche area of Faculty of Pharmacy

•Real GMP-compliant teaching/training facility for students (undergraduate & postgraduate)

Manufacture Permissible and Quality
 Pharmaceuticals
 (generic and in-house proprietary products)



# Location of Manufacturing Plant (Behind the Kulliyyah of Pharmacy)





# IIUM Pharmaceutical Manufacturing Plant - IKOP



**Main Office** 

**Production Entrance** 

## PICS/GMP Approval



Biro Pengawalan Farmaseutikal Kebangsaan National Pharmaceutical Control Bureau KEMENTERIAN KESIHATAN MALAYSIA MINISTRY OF HEALTH MALAYSIA

#### LC No. 009/12

Our Ref: (16 ) dlm.BPFK/30/12/3250 Date : 13 February 2012

#### IIUM Pharmacy Sdn. Bhd.

Kulliyah of Pharmacy, International Islamic University of Malaysia, Jalan Sultan Ahmad Shah, Bandar Indera Mahkota, 25200 Kuantan, Pahang Darul Makmur.

#### Letter of Confirmation

This is to confirm that your manufacturing premises at Kulliyah of Pharmacy, International Islamic University of Malaysia, Jalan Sultan Ahmad Shah, Bandar Indera Mahkota, 25200 Kuantan, Pahang Darul Makmur have been inspected and conforms to the requirement of Good Manufacturing Practices (GMP) in accordance to the current Pharmaceutical Inspection Co-operation Scheme (PIC/S) GMP Guides for the manufacturing of the following pharmaceuticals products:

- 1. Tablets
- 2. Capsules

Semi-solids

The premise was last inspected on 25-26 January 2012.

(WAN OTHMAN WAN ISMAIL) Senior Principal Assistant Director

Finitipal Assistant Director for Director of Regulatory Pharmacy National Pharmaceutical Control Bureau Ministry of Health Malaysia

(This document is valid only for the purpose of product registration in Malaysia only <u>AND WILL BE SUPPECEDED UPON THE ISSUANCE OF A MANUFACTURING LICENSE unless otherwise specified</u>)

Jalon Universiti, P. O. Box 319, 46730 Petaling Jaya, Selangor, Malaysia Tel.: +603 7883 5400 Fax: +603 7958 2924/7958 1312 http://www.bpfk.gov.my





#### **ACKNOWLEDGEMENT**

- ANALYTICAL BIO ANALYTICAL RESEARCH LABORATORY, IIUM
- FACULTY OF PHARMACY, IIUM
- IKOP SDN BHD
- RESEARCH MANAGEMENT CENTRE, IIUM
- NPRA
- FUNDING: MOHE, MOF Malaysia.



#### THANK YOU